Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Guselkumab (Primary) ; Ustekinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms NAVIGATE
- Sponsors Janssen Research & Development; Janssen-Cilag
- 06 Apr 2023 Results of pooled analysis from Phase 2/3 studies (X-PLORE, VOYAGE 1, VOYAGE 2, NAVIGATE, ORION, ECLIPSE, Japan registration) assessing guselkumab safety in patients with psoriasispublished in the British Journal of Dermatology
- 21 Mar 2023 Results of post-hoc analysis evaluating the subgroup of patients with residual psoriasis of mild severity , presented at the American Academy of Dermatology annual Meeting 2023
- 06 Nov 2019 Results presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research